News | April 16, 2008

FDA Clears Medtronic's Talent Abdominal Stent Graft for AAA

April 17, 2008 - Medtronic Inc. received clearance from the FDA for use of the Talent Abdominal Stent Graft on the CoilTrac Delivery System, a medical device that expands patient access to a minimally-invasive treatment option for abdominal aortic aneurysms.

The Talent Abdominal System aims to offer AAA patients minimally-invasive repair as an alternative to open surgical repair. The Talent Abdominal Stent Graft System makes endovascular repair (EVAR) accessible to reportedly an additional 20 percent of AAA patients because of its proximal aortic neck length requirement of only 10 mm. Consisting of a woven polyester membrane supported by a tubular metal lattice, the device is specifically indicated for endovascular treatment of abdominal aortic aneurysms with or without iliac involvement. The stent graft is available in diameters of up to 36 mm, as well as flared and tapered iliac limbs of 8 mm to 24 mm.

The Talent Abdominal Stent Graft is designed to provide broad patient applicability, suprarenal fixation and positioning accuracy. The stent graft features radiopaque markers for visual guidance during deployment and follow up, and the delivery system uses a single-step release mechanism for smooth deployment and a coiled rod for enhanced trackability and flexibility.

"The Talent Abdominal Stent Graft has provided excellent patient outcomes in clinical practice and in clinical study," said Dr. Michael L. Marin, professor of Vascular Surgery and chairman of the Department of Surgery at The Mount Sinai Medical Center in New York. "In my own experience, with more than 750 successful implants using the Talent System, the performance of this stent graft has been very consistent, and its safety and efficacy have been well characterized through the results of our own clinical trial."

The Medtronic-sponsored clinical study of the Talent Abdominal Stent Graft System enrolled 166 patients at 13 medical centers between February 2002 and April 2003. All 166 patients received a Talent Abdominal Stent Graft; their outcomes were compared to those of 243 patients from the Society of Vascular Surgery (SVS) Surgical Control Group at 30 days and one year post-implant. Dr. Frank Criado, director of Union Memorial Hospital's Endovascular Program in Baltimore, was the principal investigator for the study.

The study demonstrated that the Talent Abdominal Stent Graft well exceeded the SVS Control in freedom from major adverse events at 30 days, with a statistically significant difference between the two groups: Talent, 89.2 percent; SVS Control, 44.0 percent. Although patients receiving the Talent Abdominal Stent Graft were older and had a higher baseline rate of co-morbidities, at 30 days post-implant they experienced lower rates of major adverse events compared with subjects treated with open surgery. Importantly, there were no aneurysm ruptures and no conversions to open surgery in the Talent group up to 12 months after device implantation.

For more information:

Related Content

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.
FDA Concerned About Increase in stent graft Endovascular Type III Leaks
News | Stent Grafts | October 09, 2017
October 9, 2017 — The U.S.
Gore Announces First-in-Human Use of Gore TAG Conformable Thoracic Stent Graft
News | Stent Grafts | July 17, 2017
W. L. Gore & Associates Inc. announced the first patient implant of the Gore TAG Conformable Thoracic Stent Graft...
News | Stent Grafts | April 06, 2017
Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer...
Gore, Viabahn VBX Balloon Expandable Endoprosthesis, stent graft, iliac artery, FDA approval
Technology | Stent Grafts | January 31, 2017
W. L. Gore & Associates (Gore) announced that the Gore Viabahn VBX Balloon Expandable Endoprosthesis (VBX Stent...
Overlay Init